Related Experiment Video
Updated: Apr 22, 2026

MeRIP-qPCR Assay for Detecting m6A Modification Levels of Specific RNA in Osteosarcoma Cells
Published on: December 30, 2025
The m7G RNA modification in gastrointestinal cancers: mechanisms and therapeutic potential
Rui Li1, Xiaoqing Lu1, Zhiyu Guan2
1Guangdong Provincial Key Laboratory of Advanced Drug Delivery, Department of Biotechnology, Laboratory of Immunology and Inflammation, School of Life Sciences and Biopharmaceutics,Guangdong Pharmaceutical University, Guangzhou 510006, China.
Abstract:
The N7-methylguanosine (m7G) modification, an epigenetic transcriptional regulatory mechanism, plays a crucial role in the development of gastrointestinal malignant tumors. This modification, mediated by enzyme complexes such as methyltransferase-like 1 (METTL1)/WD repeat domain 4 (WDR4) and williams-beuren syndrome chromosome region 22 (WBSCR22)/tRNA methyl transferase activator subunit 11-2 (TRMT12), is widely distributed in messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), and non-coding RNA. Its abnormal expression is closely associated with the pathogenesis of various gastrointestinal tumors, including hepatocellular carcinoma, colorectal cancer, pancreatic cancer, and esophageal cancer. The METTL1/WDR4 complex enhances the translation efficiency of oncogenes by promoting tRNA m7G modification, thereby facilitating tumor cell proliferation, metastasis, and chemotherapy resistance. More importantly, the m7G modification significantly influences tumor cell resistance to chemotherapy, targeted therapy, and radiation therapy by regulating the epidermal growth factor receptor (EGFR) signaling pathway, autophagy processes, and DNA repair mechanisms. Therefore, m7G modification has dual potential as both a prognostic biomarker and a therapeutic target, and may provide a molecular basis for precision medicine in the treatment of gastrointestinal tumors.
Insights
N7-methylguanosine (m7G) modification is vital in gastrointestinal cancers. This epigenetic change impacts tumor growth, metastasis, and resistance to therapies, offering potential as a biomarker and therapeutic target.
Area of Science:
- Epigenetics
- Molecular Biology
- Oncology
Background:
- N7-methylguanosine (m7G) is an epigenetic modification regulating gene expression.
- m7G is mediated by enzyme complexes like METTL1/WDR4 and WBSCR22/TRMT12.
- This modification is found across various RNA types (mRNA, tRNA, rRNA, non-coding RNA).
Purpose of the Study:
- To investigate the role of m7G modification in gastrointestinal (GI) malignant tumors.
- To explore the association between abnormal m7G expression and GI cancer pathogenesis.
- To evaluate the potential of m7G as a prognostic biomarker and therapeutic target in GI cancers.
Main Methods:
- Review of literature on m7G modification in GI cancers.
- Analysis of the mechanisms by which m7G influences oncogene translation and therapy resistance.
- Examination of the role of m7G in regulating key signaling pathways (e.g., EGFR) and cellular processes (e.g., autophagy, DNA repair).
Main Results:
- Abnormal m7G expression is linked to hepatocellular carcinoma, colorectal cancer, pancreatic cancer, and esophageal cancer.
- The METTL1/WDR4 complex promotes oncogene translation via tRNA m7G modification, driving tumor proliferation, metastasis, and chemoresistance.
- m7G modification impacts resistance to chemotherapy, targeted therapy, and radiation by modulating EGFR signaling, autophagy, and DNA repair.
Conclusions:
- m7G modification plays a critical role in the development and progression of GI malignancies.
- m7G modification influences tumor cell resistance to various cancer treatments.
- m7G modification holds significant potential as a prognostic biomarker and therapeutic target for precision medicine in GI oncology.
Related Concept Videos
MicroRNAs
MicroRNAs
RNA Editing
RNA Stability
Experimental RNAi
Nuclear Export of mRNA

